Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Definium Therapeutics, Inc.DFTX · Entity 3884 | Director | June 11, 2026 | June 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Definium Therapeutics, Inc.
Report date June 11, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 24,289 |
Reported balance
After 2026-06-11 transaction · row 1
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 4,666 · Balance 24,289 F1: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, any unvested RSUs will vest immediately prior to the Issuer's annual meeting following the date of grant, subject the Reporting Person's continued service through the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.11 · Expires 2036-06-10 | Direct | 19,188 |
Reported balance
After 2026-06-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-11 · Grant · Acquired 19,188 · Balance 19,188 F2: The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Issuer's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, any unvested RSUs will vest immediately prior to the Issuer's annual meeting following the date of grant, subject the Reporting Person's continued service through the applicable vesting date.
F2: The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Issuer's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
OPIANT PHARMACEUTICALS, INC.
Report date March 02, 2023 · Filed March 03, 2023
Section 16 reporting ended · disclosed 2023-03-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2023-03-02 transaction · row 5
4 source rows · reconciled sequenceRow 1 · 2023-03-02 · Disposition to issuer · Disposed 37,438 · Balance 37,901 F1: Disposed of pursuant to that certain Agreement and Plan of Merger between the Issuer, Indivior Inc., and Olive Acquisition Subsidiary, Inc., dated as of November 13, 2022 (the "Merger Agreement"), in exchange for a cash payment of $20.00 per share without interest thereon (the "Merger Consideration"). Row 2 · 2023-03-02 · Disposition to issuer · Disposed 37,901 · Balance 0 F2: Disposed of pursuant to the Merger Agreement in exchange for the Merger Consideration. The number of shares disposed of reflects 37,901 shares of Common Stock upon the acceleration of vesting of restricted stock units in accordance with the Merger Agreement. Row 4 · 2023-03-02 · Grant · Acquired 6,667 · Balance 6,667 F3: 6,667 shares are represented by performance stock units ("PSUs"), the vesting of which accelerated in accordance with the Merger Agreement. Each PSU represents the Reporting Person's right to receive one share of Common Stock of Issuer. Row 5 · 2023-03-02 · Disposition to issuer · Disposed 6,667 · Balance 0 F4: Disposed of pursuant to the Merger Agreement in exchange for the Merger Consideration. The number of shares disposed of reflects 6,667 shares of Common Stock upon the acceleration of vesting of performance stock units in accordance with the Merger Agreement. |
| Common Stock par value $0.001SEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-03-02 transaction · row 3
1 source rowRow 3 · 2023-03-02 · Disposition to issuer · Disposed 5,100 · Balance 0 F1: Disposed of pursuant to that certain Agreement and Plan of Merger between the Issuer, Indivior Inc., and Olive Acquisition Subsidiary, Inc., dated as of November 13, 2022 (the "Merger Agreement"), in exchange for a cash payment of $20.00 per share without interest thereon (the "Merger Consideration"). |
| OptionSEC Table II · derivative / convertible security · Conversion / exercise price $6.00 · Expires 2023-12-30 | Direct | 0 |
Reported balance
After 2023-03-02 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-03-02 · Disposition to issuer · Disposed 25,000 · Balance 0 F5: The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. |
| OptionSEC Table II · derivative / convertible security · Conversion / exercise price $5.00 · Expires 2024-06-14 | Direct | 0 |
Reported balance
After 2023-03-02 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-03-02 · Disposition to issuer · Disposed 150,000 · Balance 0 F5: The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. |
| OptionSEC Table II · derivative / convertible security · Conversion / exercise price $7.25 · Expires 2025-10-26 | Direct | 0 |
Reported balance
After 2023-03-02 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-03-02 · Disposition to issuer · Disposed 375,000 · Balance 0 F5: The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. |
| OptionSEC Table II · derivative / convertible security · Conversion / exercise price $6.00 · Expires 2023-12-30 | Direct | 0 |
Reported balance
After 2023-03-02 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2023-03-02 · Disposition to issuer · Disposed 25,000 · Balance 0 F5: The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.62 · Expires 2029-01-14 | Direct | 0 |
Reported balance
After 2023-03-02 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2023-03-02 · Disposition to issuer · Disposed 13,200 · Balance 0 F5: The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.15 · Expires 2031-01-26 | Direct | 0 |
Reported balance
After 2023-03-02 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2023-03-02 · Disposition to issuer · Disposed 31,250 · Balance 0 F5: The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. |
| Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $13.60 · Expires 2030-01-07 | Direct | 0 |
Reported balance
After 2023-03-02 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2023-03-02 · Disposition to issuer · Disposed 27,250 · Balance 0 F5: The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to that certain Agreement and Plan of Merger between the Issuer, Indivior Inc., and Olive Acquisition Subsidiary, Inc., dated as of November 13, 2022 (the "Merger Agreement"), in exchange for a cash payment of $20.00 per share without interest thereon (the "Merger Consideration").
F2: Disposed of pursuant to the Merger Agreement in exchange for the Merger Consideration. The number of shares disposed of reflects 37,901 shares of Common Stock upon the acceleration of vesting of restricted stock units in accordance with the Merger Agreement.
F3: 6,667 shares are represented by performance stock units ("PSUs"), the vesting of which accelerated in accordance with the Merger Agreement. Each PSU represents the Reporting Person's right to receive one share of Common Stock of Issuer.
F4: Disposed of pursuant to the Merger Agreement in exchange for the Merger Consideration. The number of shares disposed of reflects 6,667 shares of Common Stock upon the acceleration of vesting of performance stock units in accordance with the Merger Agreement.
F5: The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 15, 2026 20:30 UTC | Definium Therapeutics, Inc. DFTX · Entity 3884 | GrantStock Option (Right to Buy) · Derivative | 19,188 | $0.00 Strike: $24.11 | $0.00 |
DisclosureSEC source: 0001193125-26-271164 · ownership.xml · derivative · entry 2 CRYSTAL ROGER · CIK 0001656633 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,188 Underlying: Common Shares · 19,188 shares Expires 2036-06-10 F2 · derivative.exercise_date: The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Issuer's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 20:30 UTC | Definium Therapeutics, Inc. DFTX · Entity 3884 | GrantCommon Shares | 4,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-271164 · ownership.xml · nonDerivative · entry 1 CRYSTAL ROGER · CIK 0001656633 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,289 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, any unvested RSUs will vest immediately prior to the Issuer's annual meeting following the date of grant, subject the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 20:30 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | GrantStock Option (Right to Buy) · Derivative | 75,187 | $0.00 Strike: $7.30 | $0.00 |
DisclosureSEC source: 0000950170-25-086764 · ownership.xml · derivative · entry 1 CRYSTAL ROGER · CIK 0001656633 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,187 Underlying: Common Shares · 75,187 shares Expires 2035-06-11 F1 · derivative.exercise_date: The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Company's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Company's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 10, 2024 Filed Jun 12, 2024 20:13 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | GrantStock Option (Right to Buy) · Derivative | 16,506 | $0.00 Strike: $7.25 | $0.00 |
DisclosureSEC source: 0000950170-24-072454 · ownership.xml · derivative · entry 1 CRYSTAL ROGER · CIK 0001656633 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,506 Underlying: Common Shares · 16,506 shares Expires 2034-06-09 F1 · derivative.exercise_date: The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Company's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Company's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:53 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | GrantStock Option (Right to Buy) · Derivative | 19,203 | $0.00 Strike: $3.61 | $0.00 |
DisclosureSEC source: 0000899243-23-016423 · doc4.xml · derivative · entry 2 CRYSTAL ROGER · CIK 0001656633 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,267 Underlying: Common Shares · 19,203 shares Expires 2033-06-20 F3 · derivative.exercise_date: The shares underlying the option shall vest in twelve (12) equal monthly installments starting from the grant date or upon the next Annual Meeting date, if earlier, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date. F2 · balance_after: On August 26, 2022, the Issuer effected a 1-for-15 reverse stock split (the" Reverse Stock Split"). The number of securities reported on the Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:53 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | GrantCommon Shares | 13,671 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-016423 · doc4.xml · nonDerivative · entry 1 CRYSTAL ROGER · CIK 0001656633 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,623 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one Common Share of the Issuer. The RSUs shall vest in four (4) equal quarterly installments from the grant date or upon the next Annual Meeting date, if earlier, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date. F2 · balance_after: On August 26, 2022, the Issuer effected a 1-for-15 reverse stock split (the" Reverse Stock Split"). The number of securities reported on the Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 09:18 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | Disposition to issuerStock Option (right to buy) · Derivative | 31,250 | $0.00 Strike: $12.15 | $0.00 |
DisclosureSEC source: 0001385508-23-000069 · wf-form4_167785312619410.xml · derivative · entry 12 CRYSTAL ROGER · CIK 0001656633 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 31,250 shares Expires 2031-01-26 F5 · kind: The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. F5 · derivative.exercise_date: The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 09:18 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | Disposition to issuerCommon Stock · Derivative | 27,250 | $0.00 Strike: $13.60 | $0.00 |
DisclosureSEC source: 0001385508-23-000069 · wf-form4_167785312619410.xml · derivative · entry 11 CRYSTAL ROGER · CIK 0001656633 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,250 shares Expires 2030-01-07 F5 · kind: The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. F5 · derivative.exercise_date: The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 09:18 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | Disposition to issuerStock Option (right to buy) · Derivative | 13,200 | $0.00 Strike: $14.62 | $0.00 |
DisclosureSEC source: 0001385508-23-000069 · wf-form4_167785312619410.xml · derivative · entry 10 CRYSTAL ROGER · CIK 0001656633 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,200 shares Expires 2029-01-14 F5 · kind: The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. F5 · derivative.exercise_date: The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 09:18 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | Disposition to issuerOption · Derivative | 25,000 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001385508-23-000069 · wf-form4_167785312619410.xml · derivative · entry 9 CRYSTAL ROGER · CIK 0001656633 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2023-12-30 F5 · kind: The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 09:18 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | Disposition to issuerOption · Derivative | 375,000 | $0.00 Strike: $7.25 | $0.00 |
DisclosureSEC source: 0001385508-23-000069 · wf-form4_167785312619410.xml · derivative · entry 8 CRYSTAL ROGER · CIK 0001656633 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 375,000 shares Expires 2025-10-26 F5 · kind: The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 09:18 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | Disposition to issuerOption · Derivative | 150,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001385508-23-000069 · wf-form4_167785312619410.xml · derivative · entry 7 CRYSTAL ROGER · CIK 0001656633 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires 2024-06-14 F5 · kind: The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 09:18 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | Disposition to issuerOption · Derivative | 25,000 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001385508-23-000069 · wf-form4_167785312619410.xml · derivative · entry 6 CRYSTAL ROGER · CIK 0001656633 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2023-12-30 F5 · kind: The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 09:18 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | Disposition to issuerCommon Stock | 6,667 | $20.00 | $133,340.00 |
DisclosureSEC source: 0001385508-23-000069 · wf-form4_167785312619410.xml · nonDerivative · entry 5 CRYSTAL ROGER · CIK 0001656633 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F4 · kind: Disposed of pursuant to the Merger Agreement in exchange for the Merger Consideration. The number of shares disposed of reflects 6,667 shares of Common Stock upon the acceleration of vesting of performance stock units in accordance with the Merger Agreement. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 09:18 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | GrantCommon Stock | 6,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001385508-23-000069 · wf-form4_167785312619410.xml · nonDerivative · entry 4 CRYSTAL ROGER · CIK 0001656633 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,667 F3 · kind: 6,667 shares are represented by performance stock units ("PSUs"), the vesting of which accelerated in accordance with the Merger Agreement. Each PSU represents the Reporting Person's right to receive one share of Common Stock of Issuer. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 09:18 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | Disposition to issuerCommon Stock par value $0.001 | 5,100 | $20.00 | $102,000.00 |
DisclosureSEC source: 0001385508-23-000069 · wf-form4_167785312619410.xml · nonDerivative · entry 3 CRYSTAL ROGER · CIK 0001656633 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Disposed of pursuant to that certain Agreement and Plan of Merger between the Issuer, Indivior Inc., and Olive Acquisition Subsidiary, Inc., dated as of November 13, 2022 (the "Merger Agreement"), in exchange for a cash payment of $20.00 per share without interest thereon (the "Merger Consideration"). Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 09:18 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | Disposition to issuerCommon Stock | 37,901 | $20.00 | $758,020.00 |
DisclosureSEC source: 0001385508-23-000069 · wf-form4_167785312619410.xml · nonDerivative · entry 2 CRYSTAL ROGER · CIK 0001656633 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: Disposed of pursuant to the Merger Agreement in exchange for the Merger Consideration. The number of shares disposed of reflects 37,901 shares of Common Stock upon the acceleration of vesting of restricted stock units in accordance with the Merger Agreement. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 09:18 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | Disposition to issuerCommon Stock | 37,438 | $20.00 | $748,760.00 |
DisclosureSEC source: 0001385508-23-000069 · wf-form4_167785312619410.xml · nonDerivative · entry 1 CRYSTAL ROGER · CIK 0001656633 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,901 F1 · kind: Disposed of pursuant to that certain Agreement and Plan of Merger between the Issuer, Indivior Inc., and Olive Acquisition Subsidiary, Inc., dated as of November 13, 2022 (the "Merger Agreement"), in exchange for a cash payment of $20.00 per share without interest thereon (the "Merger Consideration"). Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 16:22 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | SaleCommon Stock | 1,358 | $20.26 | $27,513.08 |
DisclosureSEC source: 0001385508-23-000034 · wf-form4_167520015002042.xml · nonDerivative · entry 1 CRYSTAL ROGER · CIK 0001656633 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,339 F1 · shares: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| January 09, 2023 Filed Jan 9, 2023 17:09 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | SaleCommon Stock | 1,183 | $20.20 | $23,896.60 |
DisclosureSEC source: 0001385508-23-000018 · wf-form4_167330214981696.xml · nonDerivative · entry 1 CRYSTAL ROGER · CIK 0001656633 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,697 F1 · shares: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| January 05, 2023 Filed Jan 5, 2023 16:52 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | SaleCommon Stock | 5,029 | $20.20 | $101,585.80 |
DisclosureSEC source: 0001385508-23-000005 · wf-form4_167295549954717.xml · nonDerivative · entry 1 CRYSTAL ROGER · CIK 0001656633 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,880 F1 · shares: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| August 11, 2022 Filed Aug 16, 2022 01:55 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | GrantDirector's Deferred Share Units · Derivative | 503,773 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-028728 · doc4.xml · derivative · entry 3 CRYSTAL ROGER · CIK 0001656633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 503,773 Underlying: Common Shares · Not disclosed shares Expires not disclosed F4 · derivative.exercise_price: Represents Directors' Deferred Share Units ("DDSUs") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the "Plan"), effective April 16, 2021. DDSUs will vest 1/3 on August 11, 2023, with the remaining portion vesting in equal monthly installments over the two years thereafter. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Common Share). Pursuant to the Plan, the fair market value of a Common Share is equal to the volume weighted average trading price of a Common Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan). F4 · price: Represents Directors' Deferred Share Units ("DDSUs") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the "Plan"), effective April 16, 2021. DDSUs will vest 1/3 on August 11, 2023, with the remaining portion vesting in equal monthly installments over the two years thereafter. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Common Share). Pursuant to the Plan, the fair market value of a Common Share is equal to the volume weighted average trading price of a Common Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan). F4 · derivative.exercise_date: Represents Directors' Deferred Share Units ("DDSUs") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the "Plan"), effective April 16, 2021. DDSUs will vest 1/3 on August 11, 2023, with the remaining portion vesting in equal monthly installments over the two years thereafter. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Common Share). Pursuant to the Plan, the fair market value of a Common Share is equal to the volume weighted average trading price of a Common Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan). F4 · derivative.expiration_date: Represents Directors' Deferred Share Units ("DDSUs") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the "Plan"), effective April 16, 2021. DDSUs will vest 1/3 on August 11, 2023, with the remaining portion vesting in equal monthly installments over the two years thereafter. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Common Share). Pursuant to the Plan, the fair market value of a Common Share is equal to the volume weighted average trading price of a Common Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan). F4 · derivative.underlying_shares: Represents Directors' Deferred Share Units ("DDSUs") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the "Plan"), effective April 16, 2021. DDSUs will vest 1/3 on August 11, 2023, with the remaining portion vesting in equal monthly installments over the two years thereafter. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Common Share). Pursuant to the Plan, the fair market value of a Common Share is equal to the volume weighted average trading price of a Common Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan). Read SEC document |
| August 11, 2022 Filed Aug 16, 2022 01:55 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | GrantStock Option (Right to Buy) · Derivative | 120,968 | $0.00 Strike: $0.66 | $0.00 |
DisclosureSEC source: 0000899243-22-028728 · doc4.xml · derivative · entry 2 CRYSTAL ROGER · CIK 0001656633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,968 Underlying: Common Shares · 120,968 shares Expires 2032-08-10 F2 · derivative.exercise_price: The option grant has an exercise price of $0.84 Canadian Dollars. This represents the exercise price in United States Dollars. F3 · derivative.exercise_date: The shares underlying the option shall vest and become exercisable 1/3 on August 11, 2023, with the remaining portion vesting in equal monthly installments over the two years thereafter, subject to the Reporting Person providing continuous service to the Issuer on each such date. Read SEC document |
| August 11, 2022 Filed Aug 16, 2022 01:55 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | GrantCommon Shares | 89,286 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-028728 · doc4.xml · nonDerivative · entry 1 CRYSTAL ROGER · CIK 0001656633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,286 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one Common Share of the Issuer. These RSUs will vest in three equal annual installments over such three-year period; provided, that in the event that the Reporting Person's continuous service as a member of the Board terminates for any reason other than for cause after the first anniversary of the grant date, a portion of these RSUs that would have vested on the next annual vesting date following the date of departure will immediately vest in full as of the date of termination of service on a prorated basis. Read SEC document |
| July 14, 2022 Filed Jul 15, 2022 16:03 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | SaleCommon Stock | 2,246 | $11.11 | $24,953.06 |
DisclosureSEC source: 0001385508-22-000109 · wf-form4_165791538445805.xml · nonDerivative · entry 1 CRYSTAL ROGER · CIK 0001656633 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,909 F1 · shares: These shares were sold to cover tax withholding obligations in connection with the vesting of performance stock units. F2 · price: This transaction was executed in multiple trades at prices ranging from $10.80 to $11.53. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 27, 2022 Filed Jun 29, 2022 16:06 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | GrantCommon Stock | 6,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001385508-22-000103 · wf-form4_165653315033706.xml · nonDerivative · entry 1 CRYSTAL ROGER · CIK 0001656633 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,155 F1 · shares: Represents the acquisition of shares upon the determination on June 27, 2020 by the Compensation and Human Capital Committee of the Board of Directors of the Issuer that the performance conditions were met with respect to a portion of the performance stock units granted to the Reporting Person on January 4, 2022. Read SEC document |
| January 27, 2022 Filed Jan 27, 2022 16:03 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | SaleCommon Stock | 1,995 | $26.15 | $52,169.25 |
DisclosureSEC source: 0001385508-22-000025 · wf-form4_164331741572395.xml · nonDerivative · entry 1 CRYSTAL ROGER · CIK 0001656633 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,488 F1 · kind: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: This transaction was executed in multiple trades at prices ranging from $25.60 to $26.70. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 10, 2022 Filed Jan 12, 2022 16:29 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | SaleCommon Stock | 1,058 | $30.49 | $32,258.42 |
DisclosureSEC source: 0001385508-22-000020 · wf-form4_164202292443156.xml · nonDerivative · entry 1 CRYSTAL ROGER · CIK 0001656633 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,483 F1 · kind: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: This transaction was executed in multiple trades at prices ranging from $28.81 to $30.79. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 04, 2022 Filed Jan 5, 2022 16:15 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001385508-22-000008 · wf-form4_164141729075458.xml · nonDerivative · entry 1 CRYSTAL ROGER · CIK 0001656633 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,541 F1 · kind: 40,000 shares are represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of Issuer, subject to the vesting schedule. One-third of the RSUs vest on the anniversary dates of January 4, 2023, January 4, 2024 and January 4, 2025, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| September 16, 2021 Filed Sep 16, 2021 16:12 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | PurchaseCommon Stock par value $0.001 | 100 | $23.44 | $2,344.00 |
DisclosureSEC source: 0001385508-21-000134 · wf-form4_163182310785742.xml · nonDerivative · entry 1 CRYSTAL ROGER · CIK 0001656633 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,100 Read SEC document |
| January 26, 2021 Filed Jan 27, 2021 16:23 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | GrantStock Option (right to buy) · Derivative | 31,250 | $0.00 Strike: $12.15 | $0.00 |
DisclosureSEC source: 0001385508-21-000019 · wf-form4_161178257624242.xml · derivative · entry 3 CRYSTAL ROGER · CIK 0001656633 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,250 Underlying: Common Stock · 31,250 shares Expires 2031-01-26 F3 · derivative.exercise_date: On January 26, 2021, the reporting person was granted an option to purchase 31,250 shares of common stock. The option vests as follows: 1/48 of the options become exercisable on the first monthly anniversary of January 26, 2021, the vesting commencement date, and 1/48 of the options become exercisable on such date every month thereafter through the fourth year anniversary of the vesting commencement date. Read SEC document |
| January 26, 2021 Filed Jan 27, 2021 16:23 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | GrantCommon Stock | 15,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001385508-21-000019 · wf-form4_161178257624242.xml · nonDerivative · entry 2 CRYSTAL ROGER · CIK 0001656633 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,541 F2 · kind: 15,650 shares are represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of Issuer, subject to the vesting schedule. One-fourth of the RSUs vest on the anniversary dates of January 26, 2022, January 26, 2023, January 6, 2024 and January 26, 2025, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| January 26, 2021 Filed Jan 27, 2021 16:23 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | GrantCommon Stock | 3,766 | $0.00 | $0.00 |
DisclosureSEC source: 0001385508-21-000019 · wf-form4_161178257624242.xml · nonDerivative · entry 1 CRYSTAL ROGER · CIK 0001656633 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,891 F1 · kind: 3,766 shares are represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of Issuer, subject to the vesting schedule. 100% of the RSUs vest on the anniversary dates of January 26, 2022, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| January 07, 2020 Filed Jan 9, 2020 16:07 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | GrantCommon Stock · Derivative | 27,250 | $0.00 Strike: $13.60 | $0.00 |
DisclosureSEC source: 0001385508-20-000011 · wf-form4_157860404223396.xml · derivative · entry 2 CRYSTAL ROGER · CIK 0001656633 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,250 Underlying: Common Stock · 27,250 shares Expires 2030-01-07 F2 · derivative.exercise_date: On January 7, 2020, the reporting person was granted an option to purchase 27,250 shares of common stock. The option vests as follows: 1/48 of the options become exercisable on the first monthly anniversary of the vesting commencement date, and 1/48 of the options become exercisable on such date every month thereafter through the fourth year anniversary of the Grant Date. Read SEC document |
| January 07, 2020 Filed Jan 9, 2020 16:07 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | GrantCommon Stock | 13,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001385508-20-000011 · wf-form4_157860404223396.xml · nonDerivative · entry 1 CRYSTAL ROGER · CIK 0001656633 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,125 F1 · shares: 13,650 shares are represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of Issuer, subject to the vesting schedule. One-fourth of the RSUs vest on the anniversary dates of January 7, 2021, January 7, 2022, January 7, 2023 and January 7, 2024, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| April 08, 2019 Filed Apr 8, 2019 17:07 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | SaleCommon Stock | 12,772 | $12.10 | $154,541.20 |
DisclosureSEC source: 0001385508-19-000039 · wf-form4_155475763759980.xml · nonDerivative · entry 3 CRYSTAL ROGER · CIK 0001656633 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,475 F1 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $12.06 to $12.20. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 05, 2019 Filed Apr 8, 2019 17:07 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | Exercise / conversionOption · Derivative | 21,472 | $7.25 Strike: $7.25 | $155,672.00 |
DisclosureSEC source: 0001385508-19-000039 · wf-form4_155475763759980.xml · derivative · entry 4 CRYSTAL ROGER · CIK 0001656633 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,000 Underlying: Common Stock · 21,472 shares Expires 2025-10-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: The option was exercised pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · derivative.exercise_date: These options may only be exercised between the following dates: (i) the first to occur of: (A) the commencement of three trials on or subsequent to October 23, 2015; or (B) (1) the approval by the U.S. Food and Drug Administration of the New Drug Application with respect to the opioid overdose reversal treatment; and (2) the commencement of two trials on or subsequent to October 23, 2015; and (ii) the Expiration Date. Read SEC document |
| April 05, 2019 Filed Apr 8, 2019 17:07 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | SaleCommon Stock | 16,001 | $11.98 | $191,691.98 |
DisclosureSEC source: 0001385508-19-000039 · wf-form4_155475763759980.xml · nonDerivative · entry 2 CRYSTAL ROGER · CIK 0001656633 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,247 F1 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $11.90 to $12.06. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 05, 2019 Filed Apr 8, 2019 17:07 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | Exercise / conversionCommon Stock | 21,472 | $7.25 | $155,672.00 |
DisclosureSEC source: 0001385508-19-000039 · wf-form4_155475763759980.xml · nonDerivative · entry 1 CRYSTAL ROGER · CIK 0001656633 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,248 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 04, 2019 Filed Apr 4, 2019 16:35 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | Exercise / conversionOption · Derivative | 22,557 | $7.25 Strike: $7.25 | $163,538.25 |
DisclosureSEC source: 0001385508-19-000037 · wf-form4_155441012914575.xml · derivative · entry 9 CRYSTAL ROGER · CIK 0001656633 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 396,472 Underlying: Common Stock · 22,557 shares Expires 2025-10-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option was exercised pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · derivative.exercise_date: These options may only be exercised between the following dates: (i) the first to occur of: (A) the commencement of three trials on or subsequent to October 23, 2015; or (B) (1) the approval by the U.S. Food and Drug Administration of the New Drug Application with respect to the opioid overdose reversal treatment; and (2) the commencement of two trials on or subsequent to October 23, 2015; and (ii) the Expiration Date. Read SEC document |
| April 04, 2019 Filed Apr 4, 2019 16:35 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | SaleCommon Stock | 16,836 | $11.93 | $200,853.48 |
DisclosureSEC source: 0001385508-19-000037 · wf-form4_155441012914575.xml · nonDerivative · entry 6 CRYSTAL ROGER · CIK 0001656633 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,776 F2 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $11.90 to $12.08. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 04, 2019 Filed Apr 4, 2019 16:35 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | Exercise / conversionCommon Stock | 22,557 | $7.25 | $163,538.25 |
DisclosureSEC source: 0001385508-19-000037 · wf-form4_155441012914575.xml · nonDerivative · entry 5 CRYSTAL ROGER · CIK 0001656633 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,612 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option was exercised pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| April 03, 2019 Filed Apr 4, 2019 16:35 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | Exercise / conversionOption · Derivative | 5,149 | $7.25 Strike: $7.25 | $37,330.25 |
DisclosureSEC source: 0001385508-19-000037 · wf-form4_155441012914575.xml · derivative · entry 8 CRYSTAL ROGER · CIK 0001656633 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 419,029 Underlying: Common Stock · 5,149 shares Expires 2025-10-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option was exercised pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · derivative.exercise_date: These options may only be exercised between the following dates: (i) the first to occur of: (A) the commencement of three trials on or subsequent to October 23, 2015; or (B) (1) the approval by the U.S. Food and Drug Administration of the New Drug Application with respect to the opioid overdose reversal treatment; and (2) the commencement of two trials on or subsequent to October 23, 2015; and (ii) the Expiration Date. Read SEC document |
| April 03, 2019 Filed Apr 4, 2019 16:35 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | SaleCommon Stock | 3,791 | $12.24 | $46,401.84 |
DisclosureSEC source: 0001385508-19-000037 · wf-form4_155441012914575.xml · nonDerivative · entry 4 CRYSTAL ROGER · CIK 0001656633 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,055 F2 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $12.22 to $12.47. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 03, 2019 Filed Apr 4, 2019 16:35 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | Exercise / conversionCommon Stock | 5,149 | $7.25 | $37,330.25 |
DisclosureSEC source: 0001385508-19-000037 · wf-form4_155441012914575.xml · nonDerivative · entry 2 CRYSTAL ROGER · CIK 0001656633 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,446 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option was exercised pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| April 02, 2019 Filed Apr 4, 2019 16:35 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | Exercise / conversionOption · Derivative | 822 | $7.25 Strike: $7.25 | $5,959.50 |
DisclosureSEC source: 0001385508-19-000037 · wf-form4_155441012914575.xml · derivative · entry 7 CRYSTAL ROGER · CIK 0001656633 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 424,178 Underlying: Common Stock · 822 shares Expires 2025-10-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option was exercised pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · derivative.exercise_date: These options may only be exercised between the following dates: (i) the first to occur of: (A) the commencement of three trials on or subsequent to October 23, 2015; or (B) (1) the approval by the U.S. Food and Drug Administration of the New Drug Application with respect to the opioid overdose reversal treatment; and (2) the commencement of two trials on or subsequent to October 23, 2015; and (ii) the Expiration Date. Read SEC document |
| April 02, 2019 Filed Apr 4, 2019 16:35 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | SaleCommon Stock | 600 | $12.48 | $7,488.00 |
DisclosureSEC source: 0001385508-19-000037 · wf-form4_155441012914575.xml · nonDerivative · entry 3 CRYSTAL ROGER · CIK 0001656633 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,846 F2 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $12.47 to $12.52. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 02, 2019 Filed Apr 4, 2019 16:35 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | Exercise / conversionCommon Stock | 822 | $7.25 | $5,959.50 |
DisclosureSEC source: 0001385508-19-000037 · wf-form4_155441012914575.xml · nonDerivative · entry 1 CRYSTAL ROGER · CIK 0001656633 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,297 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option was exercised pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| January 15, 2019 Filed Jan 17, 2019 16:18 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | GrantStock Option (right to buy) · Derivative | 13,200 | $0.00 Strike: $14.62 | $0.00 |
DisclosureSEC source: 0001385508-19-000012 · wf-form4_154775989523176.xml · derivative · entry 1 CRYSTAL ROGER · CIK 0001656633 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,200 Underlying: Common Stock · 13,200 shares Expires 2029-01-14 F1 · derivative.exercise_date: On January 15, 2019, the reporting person was granted an option to purchase 13,200 shares of common stock. The option vests as follows: 1/48 of the options become exercisable on the first monthly anniversary of the vesting commencement date, and 1/48 of the options become exercisable on such date every month thereafter through the fourth anniversary of the Grant Date. Read SEC document |
| January 08, 2019 Filed Jan 8, 2019 16:51 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | SaleCommon Stock | 11,407 | $13.27 | $151,370.89 |
DisclosureSEC source: 0001385508-19-000008 · wf-form4_154698425748836.xml · nonDerivative · entry 6 CRYSTAL ROGER · CIK 0001656633 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,475 F2 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $13.05 to $13.42. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.